Sign up today: https://investorshub.advfn.com/?imd=278713
Followers | 971 |
Posts | 383,037 |
Boards Moderated | 6 |
Alias Born | 06/24/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Harp Sangha Chairman of the Board stated, "Titan Lithium is pleased by the strong interest in our projects from industry leaders which shows that even at such an early stage, the Titan projects are a standout and a potential new focal point for Lithium in the global supply chain.
$CDSG
$SMME time to load up, green to end the week!
The JOA and PA will position Resource Rock with a 12.5% interest of the Bedias Creek and Gin Creek South assets, leaving Screaming Eagle with 77.5% interest for an initial cash compensation. Furthermore, Resource Rock has committed an additional $1,000,000 to fund workovers and recompletions on wells owned by Screaming Eagle with an additional $1,650,000 if elected to do so. Resource Rock’s past success in building successful Exploration and Production companies along with their operational expertise will greatly enhance the ability of Screaming Eagle to increase production and secure a reserve-based loan from exploration & production banks providing the capital necessary to exponentially grow the company’s daily production through workovers and newly drilled wells.
$BLFR
$SMME SmartMetric Says That, According to the Federal Reserve, Credit Cards Dominate the Payment Method Used by Consumers https://finance.yahoo.com/news/smartmetric-says-according-federal-credit-171300547.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$AVRW Announces Return of Stock Trading Back to OTCQB Market https://finance.yahoo.com/news/avenir-wellness-solutions-announces-return-100000078.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$SMME SmartMetric Says That Its Soon-to-be-Released Gen 4 Biometric Fingerprint Activated Credit Card Incorporates World's First Security Innovation Inside the Card https://finance.yahoo.com/news/smartmetric-says-soon-released-gen-150000922.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CDSG exploration update on the Titan Lithium Projects in Tanzania https://finance.yahoo.com/news/cdsg-auger-drill-program-begin-150000795.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$RNXT thin to a dollar now, big squeeze coming soon!
$SITS News: Southern ITS International, Inc. Subsidiary, Pure Oil & Gas, Inc., Reports on Oil Production Numbers and Announces a New 4-Well Drilling Project in Texas https://finance.yahoo.com/news/southern-international-inc-subsidiary-pure-133000896.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EVKRF The @IEA says 50 #lithium and 60 #nickel mines will be needed by 2030 to meet #electricvehicle mandates globally.
With #mining production timelines taking anywhere from a decade or longer, it's imperative the production of these metals is accelerated.
The @IEA says 50 #lithium and 60 #nickel mines will be needed by 2030 to meet #electricvehicle mandates globally.
— Grid Battery Metals Inc (@GRIDBattery) December 14, 2023
With #mining production timelines taking anywhere from a decade or longer, it's imperative the production of these metals is accelerated. https://t.co/AG9fh2Fess
$RNXT RenovoRx Holds a Strong Intellectual Property (IP) Portfolio with 9 Issued Patents for its Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Therapy Platform and Delivery System https://finance.yahoo.com/news/renovorx-files-international-patent-novel-133100235.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EVKRF Soil Sample Summary Results (Phase 1 Exploration Plan)
Highlights:
High grade zone in the north of > 1000ppm at lengths of 850 m x 475 m and a second high grade zone to the south of with lengths of 200 x 175 m
Clear high grade lithium zone in the northern portion of the project area is on trend with the high-grade soil samples collected in the Surge property to the north
There are 6 soil samples with Li grades over 3,000 ppm.
A total of 810 samples were collected with values ranging from 10ppm to 5610 ppm
40 samples had grades >= 1000 ppm
Using a 1000 ppm cutoff there was an average of 2010 ppm https://finance.yahoo.com/news/grid-battery-metals-announces-soil-123000328.html
$SITS Technological Investment: In 2021, the U.S. oil and gas sector spent over $6 billion on research and development.
$SITS #SITS #SouthernInternational #PureOilAndGas #Texas #America #Energy #Oil #Gas #StocksInFocus
Technological Investment: In 2021, the U.S. oil and gas sector spent over $6 billion on research and development.$SITS #SITS #SouthernInternational #PureOilAndGas #Texas #America #Energy #Oil #Gas #StocksInFocus
— Southern ITS International, Inc. (OTC:SITS) (@SITS_Inc) December 14, 2023
(the “Company” or “CDSG”) is pleased to announce it as come to a settlement agreement with Henning Mager on his note to issue 8,000,000 shares restricted for a period of 2 years. In the next quarterly filings, it will be reflected that this note has been settled in full. There are no outstanding conversions. $CDSG Note Settlement https://finance.yahoo.com/news/cdsg-note-settlement-215600693.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CDSG Note Settlement https://finance.yahoo.com/news/cdsg-note-settlement-215600693.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$MGRX Jacob Cohen, MangoRx’s Co-Founder and CEO, highlighted the significant growth potential in Mexico:
$BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX hot sector here, a market study by Groupo Knobloch estimates the annual Mexican market for ED pharmaceuticals at USD $216 million, with a 4% annual growth rate $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX a market study by Groupo Knobloch estimates the annual Mexican market for ED pharmaceuticals at USD $216 million, with a 4% annual growth rate $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX Strategic Positioning and Investor Appeal $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX the company had announced the establishment of its subsidiary, MangoRx Mexico, to spearhead its sales strategy in Mexico and Latin America for ED products. The company, renowned for its men’s health and wellness products, engaged Diaz Reus International Law Firm, a globally recognized firm, to facilitate this expansion. https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market
$MGRX MGRX had announced the establishment of its subsidiary, MangoRx Mexico, to spearhead its sales strategy in Mexico and Latin America for ED products. The company, renowned for its men’s health and wellness products, engaged Diaz Reus International Law Firm, a globally recognized firm, to facilitate this expansion. https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market
$1.00+ big breakout setting up here!
$RNXT
$MGRX a Strategic Leap in Men's Health Market $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX Yesterday #Mangoceuticles announced the upcoming release of #FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT “PRIME”, POWERED BY KYZATREX®️ (CIII #testosterone undecanoate capsules), as we now set the stage for many more Men’s #Health & #Wellness products to roll out in 2024 making #Mangorx your one stop shop for all of your #menshealth products that will make you be the best YOU can ever be!
@US_FDA
#FDA
@MariusPharma
@stoolpresidente
@barstoolsports
#Kyzatrex #TestosteroneDeficiency
@Glenny_balls
@itsRyanPownall
@adam22
@JasonScoop
@WFAN660
@ShaunMorash https://twitter.com/Mangoceuticals/status/1735324027009315325
$MGRX new partnership is set to revolutionize the Testosterone Replacement Therapy (TRT) market through their program ‘PRIME’, leveraging MangoRx’s robust telemedicine platform.$BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX big news today: Mangoceuticals ($MGRX) Partners with Marius Pharmaceuticals: A Strategic Leap in Men's Health Market $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX A Strategic Leap with Promising Returns $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
Nice buys on news! https://finance.yahoo.com/news/grid-battery-metals-announces-soil-123000328.html
$EVKRF
$MGRX has recently announced a groundbreaking Marketing Agreement with Marius Pharmaceuticals $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$MGRX News Out! Mangoceuticals ($MGRX) Partners with Marius Pharmaceuticals: A Strategic Leap in Men's Health Market $BITF $GOTU $MGRX https://www.benzinga.com/pressreleases/23/12/36234625/mangoceuticals-mgrx-partners-with-marius-pharmaceuticals-a-strategic-leap-in-mens-health-market via @Benzinga
$EVKRF Soil Sample Summary Results (Phase 1 Exploration Plan)
Highlights:
High grade zone in the north of > 1000ppm at lengths of 850 m x 475 m and a second high grade zone to the south of with lengths of 200 x 175 m
Clear high grade lithium zone in the northern portion of the project area is on trend with the high-grade soil samples collected in the Surge property to the north
There are 6 soil samples with Li grades over 3,000 ppm.
A total of 810 samples were collected with values ranging from 10ppm to 5610 ppm
40 samples had grades >= 1000 ppm
Using a 1000 ppm cutoff there was an average of 2010 ppm https://finance.yahoo.com/news/grid-battery-metals-announces-soil-123000328.html
$CDSG AUGER DRILL PROGRAM TO BEGIN ON TITAN PROPERTIES https://finance.yahoo.com/news/cdsg-auger-drill-program-begin-150000795.html $MINM $TSLA $SNGX $ILUS $BRLL $CDSG $MMSE $DBGI $AGRI $LTHM $WWR $LITOF $LTUM $ULBI $EEMMF $UAMY $TSLA $RIVN $ALMI
$BLFR Announces its Third Quarter Fiscal 2023 Financial Results, Highlights and Outlook https://finance.yahoo.com/news/updated-bluefire-equipment-corp-blfr-215000134.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $MPC $TRGP $BP $SHEL $EQNR $E $CTRA $DINO $SU $FANG $VLO $NOG $GPOR $XOM $CVX $COP $EOG $OXY $TTE $KNTK $TK
$MGRX from their news: Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.” https://finance.yahoo.com/news/mangoceuticals-introduce-prime-powered-kyzatrex-123000672.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$SMME SmartMetric Says That Its Soon-to-be-Released Gen 4 Biometric Fingerprint Activated Credit Card Incorporates World's First Security Innovation Inside the Card https://finance.yahoo.com/news/smartmetric-says-soon-released-gen-150000922.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$RNXT News: RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform https://finance.yahoo.com/news/renovorx-files-international-patent-novel-133100235.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $PFE $MRK $JNJ $MRNA $AMGN $REGN $VRTX $BNTX $SGEN $ROIV
$RNXT News: RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform https://finance.yahoo.com/news/renovorx-files-international-patent-novel-133100235.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $PFE $MRK $JNJ $MRNA $AMGN $REGN $VRTX $BNTX $SGEN $ROIV
Tim Fernback, Grid President & CEO comments "Now that the first phase of the exploration program is complete, we plan to gather as a group to interpret the geological data and plan our next steps at Texas Springs for the upcoming 2024 exploration season. We have some encouraging results to discuss, which is great news for our shareholders."
$EVKRF
$MGRX huge news hitting this week: $MGRX Dec. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals ("Marius") to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, 'PRIME' by MangoRx.
PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.
KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.
TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body's natural diurnal rhythm allowing for peak performance early in the day.
$MGRX Dec. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals ("Marius") to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, 'PRIME' by MangoRx.
PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.
KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.
TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body's natural diurnal rhythm allowing for peak performance early in the day.